Singapore, March 17 -- Eli Lilly Japan K.K. has decided to invest 20 billion yen in its Seishin Plant (Kobe City, Hyogo Prefecture), the only manufacturing base for its own products in Japan. In order to further strengthen Lilly's capacity to supply pharmaceuticals to the Japanese market, the company plans to introduce new production lines and construct a new warehouse building between 2026 and 2028, as well as optimise the Seishin Plant through the promotion of digitalisation and process automation.

At Eli Lilly Japan, it is crucial to respond quickly and flexibly to future supply expansions, driven by increasing demand for Lilly's innovative medicines and the expansion of its R&D pipeline, particularly in key areas such as diabetes, ob...